Lai-Kwon, Julia
Kelly, Brooke
Lane, Sarah
Biviano, Rebecca
Bartula, Iris
Brennan, Frank
Kivikoski, Ingrid
Thompson, Jake
Dhillon, Haryana M.
Menzies, Alexander
Long, Georgina V.
Funding for this research was provided by:
University of Sydney
Article History
Received: 29 July 2022
Accepted: 10 September 2022
First Online: 22 September 2022
Declarations
:
: The authors declare no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee at Royal Prince Alfred Hospital, Sydney, Australia (protocol number: X21-0276).
: Written informed consent was obtained from all participants in this study.
: AMM is a consultant advisor to BMS, MSD, Novartis, Roche, Pierre-Fabre, and QBiotics.GVL is a consultant advisor to Agenus, Amgen, Array Biopharma, Boehringer Ingelheim International, Bristol Myers Squibb, Evaxion, Hexal, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma, OncoSec, Pierre Fabre, Provectus, Qbiotics, Regeneron.All other authors have no declarations of interest.